ESMO Congress | Conference

Higher-Dose Rhenium-186 Nanoliposome Demonstrates OS Advantage in Recurrent Glioma

September 9th 2022

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer

September 9th 2022

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer

September 9th 2022

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

Rucaparib Demonstrates Survival Benefits in BRCA1/2-Mutated, Relapsed Ovarian Cancer.

September 9th 2022

Rucaparib elicited a progression-free survival benefit and comparable overall survival (OS) vs chemotherapy in patients with BRCA1/2-mutated, relapsed ovarian cancer who were sensitive to platinum-based chemotherapy.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC

September 24th 2021

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Frontline Bevacizumab/Erlotinib Continues to Impress in EGFR-Mutated NSCLC

September 23rd 2021

The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.

Regorafenib Confers No PFS Benefit in Advanced Chordoma

September 22nd 2021

Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.

Real-World PFS Benefit Reported With Durvalumab Regimen in Unresectable Stage III NSCLC

September 21st 2021

The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

High HER2 Expression Is Linked With Improved Outcomes With Trastuzumab Deruxtecan in HER2+ mCRC

September 21st 2021

Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.

Adavosertib Improves PFS in RAS-/TP53-Mutant Metastatic Colorectal Cancer

September 21st 2021

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Durvalumab Plus Chemotherapy Showcases Sustained OS Benefit in ES-SCLC

September 21st 2021

The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.

Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer

September 21st 2021

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Sitravatinib/Nivolumab Combo Results in Durable Response in Advanced NSCLC Following Checkpoint Inhibitors, Chemotherapy

September 21st 2021

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Blood-Based TMB Is Not Predictive of Benefit With Atezolizumab in NSCLC

September 21st 2021

Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.

Biomarkers May Predict Outcomes Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer

September 20th 2021

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

Adjuvant Atezolizumab Shows Improvement in DFS, Time to Relapse in PD-L1+ Stage II-IIIA NSCLC Subgroups

September 20th 2021

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20th 2021

First-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

September 19th 2021

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.